Novel coronavirus

Henry Schein Makes Investment to Form Strategic Partnership With Biotech Dental Group

Retrieved on: 
Friday, December 16, 2022
Health, Medical Devices, Technology, Health Technology, Software, Dental, Biotechnology, Acquisition, Disease, Collection, Privacy, Intellectual property, Annual report, Orthodontics, Failure, Terrorism, Novel coronavirus, Dentist, COVID-19, Government, FDA, EPS, Knight, Entrepreneurship, Risk, Dental, Vaccine, Ernst & Young, Affordable Care Act, Workforce, Ernst & Young Entrepreneur of the Year Award, Supply chain, Personal protective equipment, S&P, Growth, Epidemic, Pandemic, Public health, Care Act 2014, Risk factor, Health information management, Patient, Breast implant, Schein, Dentistry, Medical device, Management, Pharmaceutical industry, Biotechnology

Henry Schein and Biotech Dental will partner to bring Biotech Dentals full line of high-quality software, products, and services, including dental prostheses, clear aligners, dental implants, regenerative solutions, and biomaterials, to more dentists and dental laboratories as well as new geographies.

Key Points: 
  • Henry Schein and Biotech Dental will partner to bring Biotech Dentals full line of high-quality software, products, and services, including dental prostheses, clear aligners, dental implants, regenerative solutions, and biomaterials, to more dentists and dental laboratories as well as new geographies.
  • Henry Schein and Biotech Dental are committed to offering customers best-in-class, user-friendly, customer-centric solutions based on open architecture that help improve patient outcomes, said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
  • Biotech Dental has excelled in several of the most exciting and fastest-growing segments of the dental market, including implants and aligners.
  • Under the terms of the transaction, Henry Schein will acquire a majority ownership position in Biotech Dental.

Henry Schein Acquires Midway Dental Supply

Retrieved on: 
Monday, August 29, 2022
COVID-19, Medical Devices, Medical Supplies, Finance, Dental, Professional Services, Other Health, General Health, Health, Other Professional Services, COVID-19, Workforce, Public health, Epidemic, Government, Novel coronavirus, Terrorism, Vaccine, Risk factor, Disease, Solution, Risk, Board, Collection, Affordable Care Act, Health information management, S&P, SEC, U.S. Securities and Exchange Commission, Health, Midwestern United States, Lists of disasters, Privacy, Nasdaq, FDA, Company, Failure, Chief Dental Officer (Canada), Personal protective equipment, Annual report, Supply chain, Intellectual property, Care Act 2014, EPS, Industry, PPE, Private Securities Litigation Reform Act, Pandemic, Acquisition, Patient, Pharmaceutical industry, Management, Technology

Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States.
  • Henry Schein acquired 100% of Midway Dental, which was founded in 1987 by the late Roger Abigt, and is headquartered in Livonia, Michigan.
  • Midway Dental offers a comprehensive portfolio of dental consumable merchandise, equipment, services, and education products to nearly 7,000 customers, which will be immediately consolidated into Henry Scheins U.S.
  • More specifically, Midway Dentals customers will benefit from the vast array of Henry Schein branded products as well as the latest digital technologies that are modernizing dental practices.

Henry Schein Announces $400 Million Increase to Share Repurchase Plan

Retrieved on: 
Thursday, August 18, 2022
General Health, Health, Dental, Health Insurance, Medical Supplies, Supply chain, FDA, Epidemic, EPS, Terrorism, Intellectual property, U.S. Securities and Exchange Commission, Affordable Care Act, Risk, Public health, Lists of disasters, Industry, Senior, Failure, Growth, Private Securities Litigation Reform Act, SEC, Investment, COVID-19, Share repurchase, Care Act 2014, Board, Annual report, Workforce, Government, Disease, Personal protective equipment, Company, Program, Novel coronavirus, Vaccine, Pandemic, Risk factor, Privacy, Board of directors, Health information management, Nasdaq, S&P, Solution, Collection, Pharmaceutical industry, Technology

This program is in addition to the $400 million repurchase program announced in May 2021, which was fully executed.

Key Points: 
  • This program is in addition to the $400 million repurchase program announced in May 2021, which was fully executed.
  • This new share repurchase authorization reflects our teams commitment to delivering on our strategic priorities and creating sustainable value by investing in our business for growth, said Ronald N. South, Senior Vice President and Chief Financial Officer of Henry Schein.
  • Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology.
  • Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

Henry Schein Completes Acquisition of Condor Dental

Retrieved on: 
Thursday, July 7, 2022
Surgery, Medical Devices, Health, Dental, Medical Supplies, FDA, Health, Annual report, Acquisition, Patient, Care Act 2014, Epidemic, Supply chain, S&P, Disease, COVID-19, Condor, Workforce, MCCB, Laboratory, Pandemic, Failure, Company, Industry, Intellectual property, PPE, Public health, Breast implant, Health information management, Affordable Care Act, U.S. Securities and Exchange Commission, Henry Schein, Terrorism, Partnership, Privacy, Private Securities Litigation Reform Act, Lists of disasters, Nasdaq, Henry Schein, Inc. v. Archer & White Sales, Inc., EPS, SEC, Risk, Solution, Risk factor, Vaccine, Board, Government, Novel coronavirus, Collection, Dentistry, Pharmaceutical industry, Technology

Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of Condor Dental Research Company SA (Condor Dental), a dental distribution company that serves dental general practitioners, specialists, and laboratories in Switzerland.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC), the worlds largest provider of health care solutions to office-based dental and medical practitioners, today announced it has completed the acquisition of Condor Dental Research Company SA (Condor Dental), a dental distribution company that serves dental general practitioners, specialists, and laboratories in Switzerland.
  • The addition of Condor Dental will expand Henry Scheins entry into the Swiss market for its dental distribution business.
  • We at Henry Schein welcome our new Condor Dental colleagues and we look forward to bringing new products, services, and solutions to the Swiss dental community."
  • As part of the Henry Schein family, Condor Dental has several exciting opportunities to accelerate organic growth including geographic expansion, leveraging Henry Scheins private-label products, and accelerating participation in the digitalization of dental practices.

Henry Schein to Acquire Condor Dental, Expand Dental Sales and Service Operations in Switzerland

Retrieved on: 
Tuesday, June 7, 2022
Medical Supplies, Health, Medical Devices, Other Health, Dental, General Health, Biotechnology, Privacy, COVID-19, Company, Care Act 2014, Intellectual property, Dental, Risk factor, Health information management, EPS, Annual report, Condor, Partnership, Lists of disasters, Novel coronavirus, PPE, Government, Failure, Workforce, Nasdaq, Solution, Supply chain, FDA, Growth, Vaccine, Private Securities Litigation Reform Act, Terrorism, Laboratory, Risk, Pandemic, Affordable Care Act, Henry Schein, SEC, Breast implant, Epidemic, Industry, Board, S&P, Henry Schein, Inc. v. Archer & White Sales, Inc., Public health, Collection, U.S. Securities and Exchange Commission, Disease, Dentistry, Pharmaceutical industry, Technology

The addition of Condor Dental will expand Henry Scheins entry into the Swiss market for its dental distribution business.

Key Points: 
  • The addition of Condor Dental will expand Henry Scheins entry into the Swiss market for its dental distribution business.
  • Sales for 2021 were approximately $18 million, the majority of which were from dental consumable merchandise, with further revenue from the customization of dental practices and dental laboratory installations.
  • We look forward to welcoming the Condor Dental team to the Henry Schein family, said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
  • Henry Schein will acquire Condor Dental from MCCB Holding Sarl, a health care holding company that is wholly owned by the Libon family.

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

Retrieved on: 
Thursday, April 14, 2022
State Council of the People's Republic of China, HK, COVID-19, Internationalization, Integration, Novel coronavirus, Potyvirus, State Council, NMPA, Research, Capsid, Quarantine, Bacteria, Vehicle registration certificate, Control, RNA, Central nervous system, Medical device, Group, Patient, Fosun Pharma, PROTAC, Coronavirus, Immunomodulation, Metabolism, Human, Innovation, National Medical Products Administration, Certification, Multimedia, Colloidal gold, Joint, Virus, Pharmaceutical industry, Vaccine, Fine chemical, EU

Fosun Diagnostics' Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) adopted the in- vitro qualitative detection method of Novel Coronavirus (2019-nCoV) Nucleocapsid antigen in nasopharyngeal swabsamples from patients with respiratory and fever-related symptoms within 7 days, quarantine observers, and other antigen detection needs.

Key Points: 
  • Fosun Diagnostics' Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) adopted the in- vitro qualitative detection method of Novel Coronavirus (2019-nCoV) Nucleocapsid antigen in nasopharyngeal swabsamples from patients with respiratory and fever-related symptoms within 7 days, quarantine observers, and other antigen detection needs.
  • Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit is equipped with high sensitivity and specificity, strong anti-interference ability and no cross-reactivity among viruses and bacteria.
  • Lately, the State Council's of China under the Joint Prevention & Control for novel coronavirus pneumonia has decided to include antigen detection as a key supplement to nucleic acid detection under the "New Coronavirus Antigen Detection Application Plan (Pilot Trial)".
  • Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit will contribute and continue serving the needs of pandemic prevention and control upon its recent approval.

Precision Drilling Announces Filing of Management Information Circular and Virtual-Only Annual and Special Meeting of Shareholders

Retrieved on: 
Wednesday, March 30, 2022
Proxy, Natural gas, Novel coronavirus, Super Series, Special, Risk, Annual Meetings of the International Monetary Fund and the World Bank Group, Toronto Stock Exchange, Legislation, NYSE, High performance organization, PD, Avenue, Computershare, Health, Precision Drilling, Private Securities Litigation Reform Act, TSX, PDS, Safety, Annual general meeting, Coronavirus, Annual, COVID-19, GLOBE, Mountain, News, Precision, New, Weather, Internet, Indian stock exchange, Circular, File, Audit, Security (finance), Shareholder

CALGARY, Alberta, March 30, 2022 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (“Precision” or the “Company”) (TSX:PD; NYSE:PDS) announces today the filing and publication of its Management Information Circular (the “Circular”) issued in connection with the 2022 Annual and Special Meeting of Shareholders (the “Annual Meeting”).

Key Points: 
  • CALGARY, Alberta, March 30, 2022 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing and publication of its Management Information Circular (the Circular) issued in connection with the 2022 Annual and Special Meeting of Shareholders (the Annual Meeting).
  • Precision announces the filing of its Management Information Circular.
  • Precision also announces the date of its Annual Meeting for Holders (the Shareholders) of Common Shares (Common Shares) of Precision Drilling Corporation to be held on Thursday, May 12, 2022 at 10:00 a.m. (Mountain Time).
  • Please see below and the Circular for details and instructions on participating and voting at the Annual Meeting.

XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Retrieved on: 
Wednesday, March 23, 2022
TSX Venture Exchange, Risk, Method, Therapy, No, SEC, Publication, Patent Cooperation Treaty, Unitary state, Endothelial dysfunction, Sepsis, Intellectual property, GLOBE, Pneumonia, Viral load, Security (finance), Obesity, ADPKD, Analysis, COVID-19, Hypertension, Metabolic syndrome, Diabetic nephropathy, Coronavirus diseases, Quality of life, U.S. Securities and Exchange Commission, Genetically modified bacteria, Chronic kidney disease, NASDAQ, Mycosis, Form, Patent, Prediabetes, Death, MERS, Mortality, Uric acid, Epidemic, Severe acute respiratory syndrome coronavirus 2, Diabetes, Acute kidney injury, Patient, Infection, Company, Novel coronavirus, SARS, Xanthine oxidase, PCT, Proteinuria, Kidney, Incidence, Kidney disease, Insulin resistance, MedRxiv, News, Pharmaceutical industry, Nasdaq, Hyperuricemia, Coronavirus

This new patent filing proposes compositionsof xanthine oxidase inhibitors, uric acid lowering agents and/or anti-viral agents alone or in combination, and methods for enhancing anti-viral therapies for the treatment of individuals most at risk.

Key Points: 
  • This new patent filing proposes compositionsof xanthine oxidase inhibitors, uric acid lowering agents and/or anti-viral agents alone or in combination, and methods for enhancing anti-viral therapies for the treatment of individuals most at risk.
  • Recent peer reviewed publications suggest that individuals with hyperuricemia appear to have an increased susceptibility to develop more severe sepsis associated with COVID-19 infection.
  • Associated with modest to severe COVID-19 infection is an increased risk of a hyper-inflammatory state, increased pro-coagulative state and bacterial infection - each can contribute to acute organ injury, and death.
  • XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid.

CoreSite Announces New Senior Leadership Team

Retrieved on: 
Thursday, January 6, 2022
Technology, REIT, Other Energy, Commercial Building & Real Estate, Utilities, Construction & Property, Alternative Energy, Security, Energy, Other Technology, Software, Building Systems, Retail, Networks, Internet, Data Management, Supply Chain Management, CoreSite, Novel Coronavirus Expert Meeting, Coronavirus, Novel coronavirus, Form 10-K, Failure, Company, Forward-looking statement, NYSE, Phrase, U.S. Securities and Exchange Commission, Twitter, Security (finance), American Tower, LinkedIn, REIT, Method, Annual report, Industry, Risk management, COVID-19

CoreSite Realty Corporation, an American Tower company (NYSE: AMT), provides hybrid IT solutions that empower enterprises, cloud, network, and IT service providers to monetize and future-proof their digital business.

Key Points: 
  • CoreSite Realty Corporation, an American Tower company (NYSE: AMT), provides hybrid IT solutions that empower enterprises, cloud, network, and IT service providers to monetize and future-proof their digital business.
  • For more than 20 years, CoreSites team of technical experts have partnered with customers to optimize operations, elevate customer experience, dynamically scale, and leverage data to gain competitive edge.
  • This press release may contain forward-looking statements within the meaning of the federal securities laws.
  • All forward-looking statements reflect the Companys good faith beliefs, assumptions and expectations, but they are not guarantees of future performance.

Henry Schein Announces Retirement of Chief Financial Officer and Related Succession Plan

Retrieved on: 
Wednesday, January 5, 2022
Medical Supplies, Medical Devices, Health, Practice Management, Dental, General Health, Health information management, EPS, Family, Policy, PPE, Vaccine, COVID-19, Strategic planning, EY, Henry Schein, Novel coronavirus, Government, Growth, Technology, Failure, Company, Risk factor, Market for corporate control, Workforce, Pandemic, Risk, Lists of disasters, Annual report, Private Securities Litigation Reform Act, Disease, Affordable Care Act, SEC, Epidemic, FDA, Shareholder, Privacy, Terrorism, Board, S&P, Retirement, Confidentiality, Nasdaq, CFO, Fortune 500, Multimedia, Solution, Industry, Care Act 2014, Public health, U.S. Securities and Exchange Commission, Leadership, Corporate finance, PWC, Management, Security (finance), Pharmaceutical industry, Director

Ronald N. South, Henry Scheins Vice President, Corporate Finance since 2008 and Chief Accounting Officer since 2013, has been named his successor and will become the Companys Senior Vice President and Chief Financial Officer, effective April 29, 2022, reporting to Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.

Key Points: 
  • Ronald N. South, Henry Scheins Vice President, Corporate Finance since 2008 and Chief Accounting Officer since 2013, has been named his successor and will become the Companys Senior Vice President and Chief Financial Officer, effective April 29, 2022, reporting to Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.
  • View the full release here: https://www.businesswire.com/news/home/20220104006085/en/
    Mr. Paladinos 35 years of dedicated service at Henry Schein includes 29 years as CFO.
  • We are pleased that Steven will remain on the Board of Henry Schein and as an adviser following his retirement.
  • Additionally, Henry Schein announced that Olga Timoshkina, who joined Henry Schein this past September as Vice President, Corporate Controller, will succeed Mr. South as Vice President, Corporate Finance and Chief Accounting Officer, reporting to Mr. South.